Zim Laboratories Ltd

- The company has not planned to raise any more debt as they aim to keep the balance sheet stable and prudent, avoiding additional leverage. - A preferential equity issue has been planned to raise funds for completing remaining CapEx, regulatory compliance (CAPA), and facility upgrades. - The preferential issue is targeted at a trusted strategic investor for swift fund infusion to complete projects quickly. - About INR 35 crores of the raised funds (around 10%) are allocated for CAPA remediation efforts. - Management emphasized the preference for equity over debt to maintain financial health and support long-term growth. - No mention of any rights issue yet, though it was discussed as a theoretical alternative. - Fundraising is geared towards enabling regulatory approvals and scaling NIP and OTF products, particularly targeting EU and other regulated markets post-remediation.

- The company is completing several CapEx projects, which are contributing to increased depreciation expenses as assets get capitalized and put to use. - There is a remaining small CapEx planned to complete regulatory and facility upgrades critical for compliance and future growth. - A preferential equity raise was done to fund the CapEx quickly without increasing debt, supporting timely project completion and supply commitments. - Approximately INR 35 crores of funds raised have been allocated with about 10% set aside specifically for CAPA-related regulatory remediation activities. - The CapEx initiatives aim to increase capacity, improve cost control, margins, and regulatory compliance, particularly preparing for entry into regulated markets like the EU. - Alternate site transfers of some products are underway to de-risk timelines related to inspections and regulatory approvals. - Management focuses on completing these investments to position the company for strong growth post regulatory hurdles and scaled traction of NIP and OTF product businesses.

- The company expects steady growth in its base business with a conventional growth rate of around 10%. - NIP (Novel Innovative Products) and OTF (Oral Thin Films) businesses are showing quarter-on-quarter traction and expected to continue growing, especially in emerging and ROW (Rest of World) markets. - Post EU-GMP remediation and regulatory clearances (expected tentatively by mid-FY26), the company anticipates entering regulated markets like Europe, which will be a significant inflection point for growth. - New product registrations and approvals (e.g., TGA Australia, UK MHRA) are advancing, creating more sales opportunities. - Alternate site transfers for products are underway, aiming for additional sales from FY27. - The company plans ~20% growth in ROW markets excluding Bangladesh, with stable business in Bangladesh. - Investment in CAPEX and expanded production capacity is expected to strengthen long-term growth and improve margins. - Exact revenue numbers for NIP and OTF products post-clearance are yet to be quantified but expected to scale significantly.

- Management anticipates strong traction in regulated and emerging markets, especially with NIP (New Innovative Products) and OTF (Oral Thin Film) products gaining registrations and market presence. - Post EU-GMP remediation expected by June or July FY27, significant growth in NIP plus OTF product revenues is anticipated. - The company aims for steady growth in base business with a conventional 10% growth rate. - Margin normalization is expected with entry into Europe and regulated markets, driven by higher-margin products and stable costs. - CAPEX and regulatory investments are directed towards boosting capacity, compliance, and future revenue-generation capabilities. - The focus remains on long-term strategic initiatives to improve profitability, operational efficiency, and business continuity. - No specific EPS guidance given, but positive outlook tied to successful regulatory clearances and product launches in regulated markets.

- The company has signed agreements for key products, especially for regulated markets like Europe, which are expected to drive future growth once site transfers and regulatory approvals are completed (Page 20, 31). - Product transfer is underway for three to four products to alternate sites, which are either registered or registerable in regulated markets (Page 30-31). - After six months of stability studies post-site transfer, variation applications will be filed, taking 3-4 months for approval before manufacturing and supply can begin (Page 31). - The NIP and OTF product business currently has no sales from regulated markets, with all sales coming from Rest of World (ROW) and emerging markets (Page 25). - Growth in ROW and emerging markets is expected to continue, with a target of about 20% growth excluding Bangladesh (Page 27). - Once EU-GMP accreditation is restored (expected by June/July FY26), the company expects better visibility and scaling of NIP plus OTF products revenue (Page 8).